Mode
Text Size
Log in / Sign up
Phase 4 N=15 Treatment

An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome

Irritable Bowel Syndrome

Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Aug 2010
Primary outcome: Primary: Abdominal Pain, as Determined by Daily Pain Diaries (Patterned After Item 3 From the Brief Pain Inventory; Cleeland and Ryan, 1994). — -1.5 Units on a scale — p=<0.001

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
duloxetine (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Mclean Hospital
Primary completion
Feb 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Abdominal Pain, as Determined by Daily Pain Diaries (Patterned After Item 3 From the Brief Pain Inventory; Cleeland and Ryan, 1994).
-1.5 <0.001 sig
SECONDARY
Brief Pain Inventory
-1.5; -1.6 <.001 sig
SECONDARY
Short Form McGill Pain Questionnaire
-2.37 .001 sig
SECONDARY
Clinical Global Impression Scale
-1.7 <0.001 sig
SECONDARY
Hamilton Depression Rating Scale
6.7
SECONDARY
Hamilton Anxiety Rating Scale
-3.3 0.031 sig
SECONDARY
Irritable Bowel Syndrome-Quality of Life Scale
14.8 <0.001 sig
SECONDARY
Sheehan Disability Scale
-2.5; -1.8; -2.2 0.004 sig

Summary

We hypothesize that duloxetine treatment will be associated with improvement in symptoms of IBS, particularly abdominal pain, in individuals without comorbid major depressive disorder. During this 12-week, open-label, outpatient study, male and female subjects between the ages of 18 and 65 years who have been diagnosed with irritable bowel syndrome (IBS) will be treated with open-label duloxetine.

Eligibility Criteria

Inclusion Criteria

  • 18-65 years of age
  • Subjects must have been diagnosed with irritable bowel syndrome by a physician
  • Subjects must have had gastrointestinal symptoms for 2 or more days per week for > 6 months

Exclusion Criteria

  • Lifetime history of bipolar disorder, psychotic disorder, or obsessive-compulsive disorder
  • Current (within past 6 months) diagnosis of major depressive disorder or substance abuse disorder
  • Active suicidal/homicidal ideation
  • Pregnant women or women of child-bearing potential not using an approved methods of contraception
  • Individuals with an unstable medical condition that in the opinion of the investigator would interfere with the interpretation of symptoms
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00401258). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search